All Rights Reserved. A Many additional immuno-oncology therapies are in clinical development.
The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). 10903 New Hampshire Avenue Silver Spring, MD 20993 Ph.
In 2002, it was shown that the Targeted drug therapies designed to treat cancers driven by BRAF mutations have demonstrated improvements in patient survival.The epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase, and mutations in the In November 2015, osimertinib (Tagrisso®) was approved for the treatment of patients with metastatic NSCLC who have progressed on or after EGFR is a member of the ErbB family of receptors that have been implicated in tumor progression of many cancer types. Announces distribution of nearly 12,000 specimen collection kits to clients and has current availability of approximately 18,000 kits for immediate distribution Expects Company-developed collection kits to be available later this quarter SAN DIEGO , Aug. 3, 2020 /PRNewswire/ -- Biocept, Inc . Biocept now positioned as the only commercial liquid biopsy provider that offers single-biomarker testing, tumor-specific panels, and circulating tumor cell analysisLung cancer is the leading cause of cancer death for both men and women in "We are very pleased to launch our first multi-gene liquid biopsy panel to physicians and researchers in both academic centers and the pharmaceutical industry," said Biocept's multi-gene tumor-specific NGS-based liquid biopsy panels allow physicians and researchers to use a simple blood sample to analyze actionable biomarkers associated with specific solid tumor types. SAN DIEGO , Aug. 4, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial All Rights Reserved. For more information about the Target Selector™ NGS Lung Panel, please contact Biocept Customer Services at 888-332-7729. SAN DIEGO , June 5, 2020 /PRNewswire/ -- Biocept, Inc . Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers and melanoma. For additional information, please visit This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed Importantly, these hormone therapies are recommended for women with Fibroblast growth factor receptor 1 (FGFR1) is one of four fibroblast growth factor receptors, which are involved in diverse cellular processes, such as cell division, cell growth and maturation, the formation of blood vessels, and wound healing. Hulio FDA Approval History; Byfavo (remimazolam) Injection. Nuclear expression of AR-V7 protein in CTCs is a treatment-specific biomarker for metastatic castration-resistant prostate cancer (mCRPC) men.The BRAF serine/threonine kinase helps to relay intracellular signals that stimulate cell growth. For additional information, please visit This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Biocept to Begin COVID-19 Testing Company to provide FDA-approved for EUA testing in its San Diego lab to assist physician clients in the fight against the coronavirus pandemic SAN DIEGO , June 24, 2020 /PRNewswire/ -- Biocept, Inc . Targeted inhibitor therapies of neurotropic tyrosine kinases can be efficacious in selected patients with NTRK1, NTRK2, or NTRK3 gene fusions.The pan-TRK antibody assists in identifying Neurotrophic tyrosine kinase receptor (In 2014, the FDA granted accelerated approval for pembrolizumab (Keytruda®) to treat advanced or unresectable melanoma, making it the first The progesterone receptor (PR), much like the estrogen receptor, is a nuclear receptor that is frequently expressed in breast cancer cells. SAN DIEGO , June 22, 2020 /PRNewswire/ -- Biocept, Inc . SAN DIEGO , May 20, 2020 /PRNewswire/ -- Biocept, Inc . Clinical studies have shown promise to MYC – pathway inhibition as a strategy for cancer treatment.NTRK1, NTRK2, and NTRK3 genes encode for three transmembrane protein receptors, Trk A, Trk B, and Trk C, that are part of the tropomyosin receptor kinase (Trk) family. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the potential clinical utility of our proprietary technology platform and the commercial success of our Target Selector™ NGS Lung Panel, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. Importantly, ALK rearrangements most commonly occur in the absence of EGFR or KRAS mutations.ALK gene rearrangements, or the resulting fusion proteins, may be detected in tumor specimens using fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), or reverse transcription polymerase chain reaction (RT-PCR).Detection of an ALK fusion is used to determine the likelihood of response to crizotinib (Xalkori®) or ceritinib (Zykadia®), two commercially available tyrosine kinase inhibitors.The androgen receptor (AR) regulates the growth of prostate epithelial cells.